- Public Comps
- Virax Biolabs Group
Virax Biolabs Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Virax Biolabs Group and similar public comparables like Centogene, Lifeline Biotechnologies, Ludwig Enterprises, Integragen and more.
Virax Biolabs Group Overview
About Virax Biolabs Group
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
Founded
2021
HQ

Employees
19
Website
Financials (FY)
Market Cap
$3M
Valuation Multiples
Start free trialVirax Biolabs Group Financials
Virax Biolabs Group reported last fiscal year revenue of $12K and negative EBITDA of ($5M).
In the same fiscal year, Virax Biolabs Group generated $8K in gross profit, ($5M) in EBITDA losses, and had net loss of ($5M).
Virax Biolabs Group P&L
In the most recent fiscal year, Virax Biolabs Group reported revenue of $12K and EBITDA of ($5M).
Virax Biolabs Group is unprofitable as of last fiscal year, with gross margin of 62%, EBITDA margin of (43722%), and net margin of (40439%).
Financial data powered by Morningstar, Inc.
Virax Biolabs Group Stock Performance
Virax Biolabs Group has current market cap of $3M.
Market Cap Evolution
Virax Biolabs Group's stock price is $3.18.
Virax Biolabs Group has an EPS (earnings per share) of $-6.30.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $3M | 0.0% | - | - | - | $-6.30 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVirax Biolabs Group Valuation Multiples
Virax Biolabs Group trades at (300.5x) EV/Revenue multiple, and 0.7x EV/EBITDA.
Virax Biolabs Group Financial Valuation Multiples
As of August 21, 2026, Virax Biolabs Group has market cap of $3M.
Virax Biolabs Group has a P/E ratio of (0.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Virax Biolabs Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Virax Biolabs Group Margins & Growth Rates
Virax Biolabs Group decreased revenue by 100% but net profit grew by 3% in the last fiscal year.
In the most recent fiscal year, Virax Biolabs Group reported gross margin of 62%, EBITDA margin of (43722%), and net margin of (40439%).
Virax Biolabs Group Margins
Virax Biolabs Group Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Virax Biolabs Group Operational KPIs
Virax Biolabs Group's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.
Virax Biolabs Group's Rule of 40 is (174961%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Virax Biolabs Group's Rule of X is (175068%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Virax Biolabs Group Competitors
Virax Biolabs Group competitors include Centogene, Lifeline Biotechnologies, Ludwig Enterprises, Integragen, 2cureX, Biora Therapeutics, Epigenomics, Bluejay Diagnostics, Biomerica and Amarantus Bioscience.
Most Virax Biolabs Group public comparables operate across Diagnostics & Genomics, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.1x | - | (0.1x) | - | |||
| - | - | - | - | |||
| - | - | (3.2x) | - | |||
| (0.0x) | - | 0.7x | - | |||
| - | - | (1.4x) | - | |||
| - | - | - | - | |||
| 491.0x | - | (33.4x) | - | |||
| - | - | 0.8x | - | |||
This data is available for Pro users. Sign up to see all Virax Biolabs Group competitors and their valuation data. Start Free Trial | ||||||
Virax Biolabs Group VC Funding History
Before going public, Virax Biolabs Group raised $4M in total equity funding, across 4 rounds.
Last private valuation of Virax Biolabs Group was $8M, after raising $2M in March 2020.
Virax Biolabs Group Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Virax Biolabs Group
| When was Virax Biolabs Group founded? | Virax Biolabs Group was founded in 2021. |
| Where is Virax Biolabs Group headquartered? | Virax Biolabs Group is headquartered in United Kingdom. |
| How many employees does Virax Biolabs Group have? | As of today, Virax Biolabs Group has over 19 employees. |
| Is Virax Biolabs Group publicly listed? | Yes, Virax Biolabs Group is a public company listed on Nasdaq. |
| What is the stock symbol of Virax Biolabs Group? | Virax Biolabs Group trades under VRAX ticker. |
| When did Virax Biolabs Group go public? | Virax Biolabs Group went public in 2022. |
| Who are competitors of Virax Biolabs Group? | Virax Biolabs Group main competitors include Centogene, Lifeline Biotechnologies, Ludwig Enterprises, Integragen, 2cureX, Biora Therapeutics, Epigenomics, Bluejay Diagnostics, Biomerica, Amarantus Bioscience. |
| What is the current market cap of Virax Biolabs Group? | Virax Biolabs Group's current market cap is $3M. |
| What is the current revenue of Virax Biolabs Group? | Virax Biolabs Group's last fiscal year revenue is $12K. |
| What is the current revenue growth of Virax Biolabs Group? | Virax Biolabs Group revenue growth (vs. last FY) is (100%). |
| What is the current EV/Revenue multiple of Virax Biolabs Group? | Current revenue multiple of Virax Biolabs Group is (300.5x). |
| Is Virax Biolabs Group profitable? | No, Virax Biolabs Group is not profitable. |
| How many companies Virax Biolabs Group has acquired to date? | Virax Biolabs Group hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Virax Biolabs Group has invested to date? | Virax Biolabs Group hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Virax Biolabs Group
Lists including Virax Biolabs Group
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




